Back in September 2025, I wrote an article on LifeMD ( LFMD ) and assigned my first ever Strong Buy rating. I saw LifeMD as an underappreciated telehealth company with a similar business model toI am a software developer by trade who focuses on finding value in the market wherever it may lie. I'm looking mainly in small caps for opportunities that provide asymmetric upside. I'm also interested in generating income through my investments, which leads me to look at high dividend yields that are sustainable. T ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Confe ...

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures [1][2] Group 1 - There is no stock, option, or similar derivative position in any of the companies mentioned [1] - The article expresses personal opinions and is not receiving compensation beyond Seeking Alpha [1] - No business relationship exists with any company whose stock is mentioned [1] Group 2 - Past performance is not indicative of future results [2] - No investment recommendations or advice are provided for suitability to particular investors [2] - The views expressed may not reflect those of Seeking Alpha as a whole [2]

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures [1][2] Group 1 - There is no stock, option, or similar derivative position in any of the companies mentioned [1] - The article expresses personal opinions and is not receiving compensation beyond Seeking Alpha [1] - The authors are third-party contributors, which may include both professional and individual investors [2]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of LifeMD, Inc. related to misrepresentation of the company's competitive position and financial guidance [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether LifeMD's officers and directors have failed in their fiduciary responsibilities to shareholders [1]. - A federal securities lawsuit claims that insiders at LifeMD misrepresented the company's competitive position and failed to disclose rising customer acquisition costs [2]. Group 2: Financial Misrepresentation - LifeMD's competitive position was allegedly overstated, leading to misleading statements about its business and operations [2]. - The lawsuit indicates that the decision to raise LifeMD's 2025 guidance was reckless due to unaccounted rising customer acquisition costs in its RexMD segment and for obesity treatment drugs [2].

Group 1: Market Activity - Several biotech and healthcare companies experienced notable gains in after-hours trading, indicating renewed investor interest in drug development and healthcare services [1] - Zentalis Pharmaceuticals, Inc. (ZNTL) surged 17.65% to close at $4.40, attributed to a recent corporate update that boosted investor confidence in its azenosertib development program [2] - LifeMD, Inc. (LFMD) climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability [3] Group 2: Company-Specific Developments - NanoViricides, Inc. (NNVC) advanced 11.11% to $1.24, driven by speculative interest despite no recent news [4] - Intelligent Bio Solutions Inc. (INBS) posted a 9.10% increase, closing at $19.55, continuing to gain momentum from overall investor enthusiasm in the biotech sector [4] - IO Biotech, Inc. (IOBT) rose 6.49% to $0.60, suggesting bargain-hunting activity at lower price levels [5] Group 3: Financing and Agreements - China SXT Pharmaceuticals, Inc. (SXTC) advanced 2.06% to $18.29 after disclosing a definitive agreement for the purchase of 66,666,666 Class A ordinary shares at $0.15 per share, highlighting efforts to strengthen its capital position [6]

Core Viewpoint - LifeMD, Inc. has successfully closed a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability to support its growth initiatives and enhance financial flexibility [1][2]. Financial Details - The revolving credit facility has a maturity date of January 2, 2029, with $30 million of committed availability and an accordion option of up to $20 million [1]. - As of the closing date, LifeMD has not drawn any balance on the facility, indicating sufficient cash on hand and expected cash flow for its organic growth [1]. - The loans under the facility will bear interest based on either Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus a spread of 50 to 125 basis points [3]. - Fees on the committed unused portion of the facility range from 0.225% to 0.30%, depending on leverage, and there is no upfront fee for LifeMD [3]. Company Overview - LifeMD is a leading provider of virtual primary care and pharmacy services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [4]. - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [4].

Group 1: Fox and Flutter's FanDuel - Fox has the option to acquire an 18.6% stake in Flutter's FanDuel, which holds over 30% market share in U.S. sports betting [2][3] - The option originated from Fox's 2019 investment in The Stars Group, which was later folded into FanDuel after Flutter's acquisition [3] - CEO Lachlan Murdoch confirmed Fox's intention to exercise the option, with a potential FanDuel valuation around $35 billion [4] Group 2: Market Reactions and Other News - Analysts view the FanDuel option as a hidden asset value for Fox, with varying opinions on the timing for exercising the option [5] - LifeMD and GoodRx stocks rose after adding Novo Nordisk's Wegovy weight-loss pill to their offerings, priced at $149 per month [5] - Samsung and SK hynix are expected to raise server memory prices by up to 70% in Q1 due to increased AI demand [6]

Group 1 - LifeMD (LFMD) and GoodRx (GDRX) shares increased in premarket trading following the announcement of Novo Nordisk's (NVO) Wegovy pill availability in their product offerings [2] - The announcement from the Danish drugmaker indicates a strategic partnership that could enhance the market presence of both LifeMD and GoodRx [2] - Wegovy is positioned as a significant product in the weight management sector, reflecting the growing demand for obesity treatments [2]

Core Viewpoint - LifeMD, Inc. has expanded its virtual weight management offerings by introducing Novo Nordisk's Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, available for eligible patients at a starting price of $149 per month [1][5]. Group 1: Product Offering - LifeMD is now offering Wegovy (semaglutide) through its telehealth platform, enhancing access to affordable branded treatment options for weight management [1]. - Wegovy is indicated for reducing excess body weight, supporting long-term weight maintenance, and lowering the risk of major adverse cardiovascular events, with a Phase 3 trial showing a mean weight loss of 16.6% compared to 2.7% with placebo [3]. - The oral formulation of Wegovy is expected to attract patients who are hesitant to use injectable treatments, thereby broadening access to GLP-1 therapies [3]. Group 2: Collaboration and Integration - LifeMD's collaboration with Novo Nordisk is highlighted, with LifeMD being featured as a trusted telehealth provider on NovoCare and Wegovy websites, reflecting the demand for convenient access to GLP-1 therapies [2]. - The integration with NovoCare Pharmacy allows streamlined access to both injectable and oral GLP-1 medications, including Wegovy and Ozempic, at competitive cash-pay pricing [4]. - LifeMD provides a comprehensive experience that includes virtual visits, ongoing clinical oversight, diagnostic testing, pharmacy fulfillment, and simplified billing [4]. Group 3: Pricing and Availability - Wegovy 1.5mg and 4mg pills are available for $149 per month, with future pricing adjustments planned for April 15, 2026, where 4mg will be priced at $199 and higher doses at $299 per month [5].